Literature DB >> 17351456

Metformin-associated lactic acidosis in a burn patient.

Paul J Riesenman1, Susan S Braithwaite, Bruce A Cairns.   

Abstract

Hyperglycemia commonly is observed as part of the hypermetabolic response to severe burn injury. In routine burn care, physicians use interventions to address and reduce the complications of this stress-induced hyperglycemia. Metformin (1,1-dimethylbiguanide), an orally administered hyperglycemic medication, has been used previously to modulate the stress-induced hyperglycemic response in nondiabetic burn patients. The use of this medication in nonburn diabetic patients has been associated with the development of lactic acidosis. We present an acute burn patient who developed lactic acidosis while receiving metformin for management of his diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351456     DOI: 10.1097/BCR.0B013E318031A1FE

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  4 in total

1.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 2.  Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.

Authors:  Gerd G Gauglitz; David N Herndon; Marc G Jeschke
Journal:  J Burn Care Res       Date:  2008 Sep-Oct       Impact factor: 1.845

Review 3.  The role of hyperglycemia in burned patients: evidence-based studies.

Authors:  Gabriel A Mecott; Ahmed M Al-Mousawi; Gerd G Gauglitz; David N Herndon; Marc G Jeschke
Journal:  Shock       Date:  2010-01       Impact factor: 3.454

4.  Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle.

Authors:  Harumasa Nakazawa; Marina Yamada; Tomokazu Tanaka; Joshua Kramer; Yong-Ming Yu; Alan J Fischman; J A Jeevendra Martyn; Ronald G Tompkins; Masao Kaneki
Journal:  PLoS One       Date:  2015-01-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.